Partnership For Cures
Partnership For Cures consistently generates revenue surpluses and has grown assets significantly without reporting officer compensation.
EIN: 203620169 · Chicago, IL · NTEE: H12 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $3.9M |
| Total Expenses | $1.6M |
| Program Spending | 85% |
| CEO/Top Officer Pay | $4 |
| Net Assets | $3.4M |
| Transparency Score | 85/100 |
Is Partnership For Cures Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Partnership For Cures directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Partnership For Cures
Partnership For Cures (EIN: 203620169) is a nonprofit organization based in Chicago, IL, classified under NTEE code H12. The organization reported total revenue of $3.9M and total assets of $7.5M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Partnership For Cures's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Partnership For Cures is a mid-size nonprofit that has been operating for 21 years, with 14 years of IRS 990 filings on record (2011–2024). Revenue has grown at a compound annual rate of 4.4%.
Key Financial Metrics (2024)
From the most recent IRS 990 filing on record:
| Total Revenue | $1.8M |
| Total Expenses | $1.6M |
| Surplus / Deficit | +$170K |
| Total Assets | $4.9M |
| Total Liabilities | $1.5M |
| Net Assets | $3.4M |
| Operating Margin | 9.6% |
| Debt-to-Asset Ratio | 29.8% |
| Months of Reserves | 36.5 months |
Financial Health Grade: A
In 2024, Partnership For Cures reported a surplus of $170K with revenue exceeding expenses, holds 36.5 months of operating reserves (strong position), has a debt-to-asset ratio of 29.8% (moderate leverage).
Financial Trends
Over 14 years of filings (2011–2024), Partnership For Cures's revenue has grown at a compound annual growth rate (CAGR) of 4.4%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2024 | -19.5% | +23.9% | +6.9% |
| 2023 | +48.4% | +26.0% | +31.8% |
| 2022 | -30.1% | -18.9% | +19.7% |
| 2021 | -17.4% | -53.8% | +59.0% |
| 2020 | +104.8% | +88.6% | -1.0% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 2000 |
| IRS Ruling Date | 2005 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Partnership For Cures with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Partnership For Cures allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2024)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $170K, with revenue exceeding expenses.
- Debt-to-asset ratio: 29.8%.
Executive Compensation Analysis
Executive compensation is reported as 0% across all available filings, indicating that the organization's leadership either serves on a volunteer basis or is compensated through mechanisms not categorized as officer compensation on the 990, which is highly unusual for an organization of its size with nearly $4 million in latest revenue.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Partnership For Cures's IRS 990 filings:
- Lack of detailed expense breakdown (program, admin, fundraising) in provided data makes full efficiency assessment difficult.
- Zero reported officer compensation for an organization with nearly $4 million in latest revenue is unusual and could indicate compensation is reported in other categories or that leadership is entirely volunteer, which warrants further investigation for clarity.
Strengths
The following positive indicators were identified for Partnership For Cures:
- Consistent revenue growth, with latest revenue at $3,912,759.
- Significant asset growth, from $1,398,699 in 201507 to $4,893,129 in 202407.
- Consistent generation of revenue surpluses in recent years (e.g., $1,777,296 revenue vs. $1,607,374 expenses in 202407).
- No reported officer compensation, suggesting high resource allocation to mission or volunteer leadership.
- Healthy asset-to-liability ratio, indicating strong financial stability.
Frequently Asked Questions about Partnership For Cures
Is Partnership For Cures a legitimate charity?
Partnership For Cures (EIN: 203620169) is a registered tax-exempt nonprofit based in Illinois. Our AI analysis gives it a Mission Score of 85/100. It has 14 years of IRS 990 filings on record. Total revenue: $3.9M. 2 red flags identified. 5 strengths noted. Financial health grade: A.
How does Partnership For Cures spend its money?
Partnership For Cures directs 85% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Partnership For Cures tax-deductible?
Partnership For Cures is registered as a tax-exempt nonprofit (EIN: 203620169). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Partnership For Cures CEO make?
Partnership For Cures's highest-compensated officer earns $4 annually. The organization reported $3.9M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
What percentage of Partnership For Cures's spending goes to programs?
Partnership For Cures directs 85% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Partnership For Cures compare to similar nonprofits?
With a transparency score of 85/100 (Excellent), Partnership For Cures is above average for NTEE category H12 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Partnership For Cures located?
Partnership For Cures is headquartered in Chicago, Illinois and files with the IRS under EIN 203620169. It is classified under NTEE code H12.
How many years of IRS 990 filings does Partnership For Cures have?
Partnership For Cures has 14 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $3.9M in total revenue.
Is Partnership For Cures a good charity?
Based on the provided data, Partnership For Cures appears to be a financially sound organization with consistent revenue growth and asset accumulation. The absence of reported officer compensation is a notable positive, suggesting resources are directed towards its mission. However, a detailed breakdown of program, administrative, and fundraising expenses would provide a more complete picture of its operational efficiency.
How has Partnership For Cures' financial health changed over time?
Partnership For Cures has shown significant financial improvement. Revenue has generally increased from $745,520 in 201507 to $1,777,296 in 202407, and assets have grown substantially from $1,398,699 to $4,893,129 over the same period. The organization has consistently generated surpluses in recent years, indicating strong financial management.
What is the trend in Partnership For Cures' expenses?
Expenses have generally increased over time, from $938,452 in 201507 to $1,607,374 in 202407. However, in recent periods (202107-202407), expenses have been consistently lower than revenue, indicating efficient spending relative to income.
Filing History
IRS 990 filing history for Partnership For Cures showing financial trends over 14 years of public records:
Over 14 years of IRS 990 filings (2011–2024), Partnership For Cures's revenue has grown by 75.8%, moving from $1.0M to $1.8M. Total assets increased by 352.9% over the same period, from $1.1M to $4.9M. Total functional expenses rose by 17%, from $1.4M to $1.6M. In its most recent filing year (2024), Partnership For Cures reported a surplus of $170K, with revenue exceeding expenses. The organization holds $1.5M in liabilities against $4.9M in assets (debt-to-asset ratio: 29.8%), resulting in net assets of $3.4M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2024 | $1.8M | $1.6M | $4.9M | $1.5M | — | View 990 |
| 2023 | $2.2M | $1.3M | $4.6M | $1.3M | — | View 990 |
| 2022 | $1.5M | $1.0M | $3.5M | $1.1M | — | View 990 |
| 2021 | $2.1M | $1.3M | $2.9M | $1.0M | — | View 990 |
| 2020 | $2.6M | $2.8M | $1.8M | $790K | — | View 990 |
| 2019 | $1.3M | $1.5M | $1.8M | $655K | — | View 990 |
| 2018 | $1.0M | $1.1M | $1.7M | $273K | — | View 990 |
| 2017 | $872K | $978K | $1.5M | $278K | — | View 990 |
| 2016 | $1.0M | $844K | $1.4M | $223K | — | View 990 |
| 2015 | $746K | $938K | $1.4M | $468K | — | View 990 |
| 2014 | $1.4M | $830K | $1.4M | $238K | — | View 990 |
| 2013 | $536K | $816K | $908K | $315K | — | View 990 |
| 2012 | $658K | $469K | $1.3M | $415K | — | View 990 |
| 2011 | $1.0M | $1.4M | $1.1M | $397K | — | View 990 |
Year-by-Year Financial Summary
- 2024: Revenue of $1.8M, expenses of $1.6M, and assets of $4.9M (revenue -19.5% year-over-year).
- 2023: Revenue of $2.2M, expenses of $1.3M, and assets of $4.6M (revenue +48.4% year-over-year).
- 2022: Revenue of $1.5M, expenses of $1.0M, and assets of $3.5M (revenue -30.1% year-over-year).
- 2021: Revenue of $2.1M, expenses of $1.3M, and assets of $2.9M (revenue -17.4% year-over-year).
- 2020: Revenue of $2.6M, expenses of $2.8M, and assets of $1.8M (revenue +104.8% year-over-year).
- 2019: Revenue of $1.3M, expenses of $1.5M, and assets of $1.8M (revenue +20.1% year-over-year).
- 2018: Revenue of $1.0M, expenses of $1.1M, and assets of $1.7M (revenue +20.0% year-over-year).
- 2017: Revenue of $872K, expenses of $978K, and assets of $1.5M (revenue -15.3% year-over-year).
- 2016: Revenue of $1.0M, expenses of $844K, and assets of $1.4M (revenue +38.2% year-over-year).
- 2015: Revenue of $746K, expenses of $938K, and assets of $1.4M (revenue -45.2% year-over-year).
- 2014: Revenue of $1.4M, expenses of $830K, and assets of $1.4M (revenue +153.6% year-over-year).
- 2013: Revenue of $536K, expenses of $816K, and assets of $908K (revenue -18.5% year-over-year).
- 2012: Revenue of $658K, expenses of $469K, and assets of $1.3M (revenue -34.9% year-over-year).
- 2011: Revenue of $1.0M, expenses of $1.4M, and assets of $1.1M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Partnership For Cures:
Data Sources and Methodology
This transparency report for Partnership For Cures is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.